Mitotech

Core business

Mitotech S.A. is a Luxembourg-based clinical stage biotechnology company developing novel drugs for treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria directed cardiolipin peroxidation inhibitors. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.

Products & services

Company’s most clinically advanced drug formulation is Visomitin – ophthalmic solution of SkQ1 developed for several age-related eye disorders, including Dry Eye Disease, where Mitotech reached Phase 3 clinical stage in the U.S. Mitotech is also approaching clinical stage of development of its oral drug formulation for treatment of Multiple Sclerosis, Alzheimer’s Disease and other disorders.